Clinical significance of BPI-ANCA in patients with cystic fibrosis: a single center prospective study

Abstract

Recurrent pulmonary exacerbation due to infection and inflammation remain the major cause of mortality and morbidity in patients with cystic fibrosis (CF). Increased levels of BPI-ANCA have been linked to Pseudomonas colonization and pulmonary exacerbations in patients with CF. The majority of these studies were done in Europe, and it is unclear whether similar findings are true in CF patients who lives in United States. In our single center study of 47 patients with CF, the prevalence of BPI-ANCA was 19% at baseline and 15% at annual follow-up visit. Overall, there were no statistical differences noted in FEV1 and frequency of pulmonary exacerbations in CF patients who were positive for BPI-ANCA compared to those who were negative for BPI-ANCA. The role of BPI-ANCA in patients with CF still remains unclear.

On the problem of differential diagnosis in the detection of antineutrophil cytoplasmic antibodies

“…Иммуносупрессивная терапия AAB иногда провоцирует ЗНО и в то же время химиотерапия у пациентов со ЗНО может привести к развитию ААВ [88,89]. AНЦA к ПР3 или МПO встречаются и при рецидивирующем полихондрите [90], а среди неревматических заболеванийпри муковисцидозе [91] и синдроме холестериновой атероэмболии [92], что может привести к диагностическим ошибкам.…”